Novo Nordisk (NVO) has released an update.
Novo Nordisk A/S, a Danish global healthcare leader, has actively pursued its share repurchase program, announcing the buyback of B shares worth DKK 2.4 billion as part of a larger DKK 20 billion initiative set to span 12 months from February 2024. As of August 23, 2024, the company has acquired over 11 million B shares at an average price of DKK 879.94, reflecting its robust investment back into the company. This strategic move underlines Novo Nordisk’s ongoing commitment to its shareholders and its mission to combat serious chronic diseases.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
